Lixte Biotechnology Statistics
Share Statistics
Lixte Biotechnology has 2.68M
shares outstanding. The number of shares has increased by 19.33%
in one year.
| Shares Outstanding | 2.68M |
| Shares Change (YoY) | 19.33% |
| Shares Change (QoQ) | 19.33% |
| Owned by Institutions (%) | 1.49% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,338 |
| FTD / Avg. Volume | 6.99% |
Short Selling Information
The latest short interest is 32.59K, so 1.21% of the outstanding
shares have been sold short.
| Short Interest | 32.59K |
| Short % of Shares Out | 1.21% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 1.51 |
Valuation Ratios
The PE ratio is -1.27 and the forward
PE ratio is null.
Lixte Biotechnology's PEG ratio is
0.03.
| PE Ratio | -1.27 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 5.52 |
| P/FCF Ratio | -1.44 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Lixte Biotechnology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.26,
with a Debt / Equity ratio of 0.
| Current Ratio | 3.26 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 212.4 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,792,982.5 |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -42.97% in the
last 52 weeks. The beta is 0.4, so Lixte Biotechnology's
price volatility has been higher than the market average.
| Beta | 0.4 |
| 52-Week Price Change | -42.97% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.73 |
| Relative Strength Index (RSI) | 56.67 |
| Average Volume (20 Days) | 19,136 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.57M |
| Net Income | -3.59M |
| EBITDA | -3.57M |
| EBIT | -3.6M |
| Earnings Per Share (EPS) | -1.59 |
Full Income StatementBalance Sheet
The company has 1.04M in cash and 0 in
debt, giving a net cash position of 1.04M.
| Cash & Cash Equivalents | 1.04M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -52.07M |
| Total Assets | 1.51M |
| Working Capital | 1.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -3.16M
and capital expenditures 0, giving a free cash flow of -3.16M.
| Operating Cash Flow | -3.16M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.16M |
| FCF Per Share | -1.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
